Elite Pharmaceuticals Inc (ELTP)

[WeeZuhl]

I think Glenmark will be our partner for the Unique ADT IR line of products.

I bet Glenmark will also get isradipine when we bring it home in October. We already manufacture it at the Northvale plant, and Glenmark will have it plugged in and ready when STEADY-PDIII results are published in early 2019. Many expect this Phase 3 trial will show isradipine is effective to slow down progression of Parkinson's Disease, and with a million patients and only one competitor, Elite will need a high-caliber partner like Glenmark.






https://seekingalpha.com/article/4182056-elite-pharmaceuticals-inc-eltp-ceo-nasrat-hakim-q4-2018-results-earnings-call-transcript?part=single



Nasrat Hakim:

...the contract with Epic regarding this specific manufacturing and supply agreement expires in October of 2018. We intend to bring all of these products home to Elite and we intend to launch them by 2019.

Carter Ward:

...the Alliance with Glenmark includes the ability to expand and add more products. Glenmark's marketing capabilities and resources are well established and they are significant. Expanding the product lines in our alliance is something both of us are interested in. So, the potential is great, and we're optimistic as to the future of the Elite-Glenmark strategic alliance.

https://www.michaeljfox.org/foundation/news-detail.php?record-pace-recruitment-for-steady-pd-iii-lays-foundation-for-other-investigations

One such study is STEADY-PD III, a Phase III trial evaluating the ability of isradipine (a blood pressure drug) to slow or stop PD progression. This National Institutes of Health (NIH)-funded study, however, completed recruitment six months ahead of schedule, driving a potential new PD therapy forward faster and setting precedent for future investigations.

Isradipine is approved by the U.S. Food and Drug Administration (FDA) to treat high blood pressure. Pre-clinical studies and an MJFF-funded Phase II trial demonstrated isradipine has potential to prevent death of dopamine-producing cells and slow Parkinson's progression. An example of a repurposed therapy in PD, isradipine must still undergo rigorous testing to prove it is safe and efficacious for people with Parkinson's.